DK1326838T3 - Nye krystalformer af en inhibitor af faktor xa - Google Patents

Nye krystalformer af en inhibitor af faktor xa

Info

Publication number
DK1326838T3
DK1326838T3 DK01979459T DK01979459T DK1326838T3 DK 1326838 T3 DK1326838 T3 DK 1326838T3 DK 01979459 T DK01979459 T DK 01979459T DK 01979459 T DK01979459 T DK 01979459T DK 1326838 T3 DK1326838 T3 DK 1326838T3
Authority
DK
Denmark
Prior art keywords
inhibitor
factor
crystal forms
novel crystal
novel
Prior art date
Application number
DK01979459T
Other languages
Danish (da)
English (en)
Inventor
Rick G Woodward
David S Teager
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1326838T3 publication Critical patent/DK1326838T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01979459T 2000-10-05 2001-10-04 Nye krystalformer af en inhibitor af faktor xa DK1326838T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23831600P 2000-10-05 2000-10-05
GBGB0108903.6A GB0108903D0 (en) 2000-10-05 2001-04-10 Novel crystalline forms of a factor Xa inhibitor
PCT/US2001/031087 WO2002028836A1 (en) 2000-10-05 2001-10-04 Novel crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
DK1326838T3 true DK1326838T3 (da) 2008-09-22

Family

ID=22897372

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01979459T DK1326838T3 (da) 2000-10-05 2001-10-04 Nye krystalformer af en inhibitor af faktor xa

Country Status (14)

Country Link
US (1) US7034160B2 (ja)
EP (1) EP1326838B1 (ja)
JP (1) JP4177663B2 (ja)
AT (1) ATE396177T1 (ja)
AU (2) AU2002211425B2 (ja)
CA (1) CA2424565C (ja)
CY (1) CY1108224T1 (ja)
DK (1) DK1326838T3 (ja)
ES (1) ES2304396T3 (ja)
GB (1) GB0108903D0 (ja)
IL (1) IL155189A (ja)
MX (1) MXPA03002067A (ja)
PT (1) PT1326838E (ja)
WO (1) WO2002028836A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
EA025572B1 (ru) * 2011-03-29 2017-01-30 Санофи Лекарственные формы отамиксабана с улучшенной стабильностью
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
AU2012234325B2 (en) 2011-03-29 2016-08-11 Sanofi Benzoic acid salt of Otamixaban
SG11201408067YA (en) 2012-06-04 2015-01-29 Pharmacyclics Inc Crystalline forms of a bruton's tyrosine kinase inhibitor
AU2015300798A1 (en) 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
FI3265084T3 (fi) 2015-03-03 2024-02-21 Pharmacyclics Llc Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
HU228355B1 (en) * 1996-01-02 2013-03-28 Aventis Pharma Inc Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides

Also Published As

Publication number Publication date
AU2002211425B2 (en) 2006-03-02
MXPA03002067A (es) 2003-06-24
ES2304396T3 (es) 2008-10-16
IL155189A (en) 2011-11-30
JP4177663B2 (ja) 2008-11-05
WO2002028836A9 (en) 2003-11-20
GB0108903D0 (en) 2001-05-30
AU1142502A (en) 2002-04-15
EP1326838A1 (en) 2003-07-16
JP2004521082A (ja) 2004-07-15
WO2002028836A1 (en) 2002-04-11
EP1326838B1 (en) 2008-05-21
ATE396177T1 (de) 2008-06-15
US7034160B2 (en) 2006-04-25
CY1108224T1 (el) 2014-02-12
PT1326838E (pt) 2008-07-08
CA2424565C (en) 2011-04-26
CA2424565A1 (en) 2002-04-11
US20030225144A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
ATE440833T1 (de) Antithrombotische diamide
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
DE60324544D1 (de) Muskarin antagonisten
CY1108224T1 (el) Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
HUP0301076A2 (hu) Linezolid II kristályforma és előállítása
SE0302139D0 (sv) Novel compounds
ATE291021T1 (de) Oxytocin agonisten
ATE427953T1 (de) Fondaparinux- natrium zusammenstellung von hoher reinheit
SE0403171D0 (sv) New compounds
DE50113345D1 (de) Arginin-mimetika als faktor xa-inhibitoren
SE0103710D0 (sv) Compounds
UY27410A1 (es) Formas novedosas crudas cristalinas
RS94603A (en) Novel compounds and compositions as cathepsin inhibitors
NO20052994L (no) Nye fosforamidderivater.
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
SE9903290D0 (sv) Novel compounds
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
SE0302755D0 (sv) Novel compounds